US FDA approves Bracco’s Gadopiclenol injection, Vueway
The US FDA has approved Bracco Diagnostics Gadopiclenol injection, a new, highly stable macrocyclic gadolinium-based contrast agent (GBCA), which shows the highest relaxivity compared to all the other GBCAs available in the United States. Bracco Diagnostics is the United States subsidiary of Bracco Imaging, a world leader in diagnostic imaging.